Entellus Medical Stock Price, News & Analysis (NASDAQ:ENTL)

$24.63 0.33 (1.36 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$24.63
Today's Range$24.24 - $24.75
52-Week Range$11.47 - $24.88
Volume388,451 shs
Average Volume722,815 shs
Market Capitalization$619.14 million
P/E RatioN/A
Dividend YieldN/A
Beta0.02

About Entellus Medical (NASDAQ:ENTL)

Entellus Medical logoEntellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.

Receive ENTL News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTL
CUSIPN/A
Phone763-463-1595

Debt

Debt-to-Equity Ratio0.32%
Current Ratio1.92%
Quick Ratio1.71%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$75.18 million
Price / Sales8.35
Cash FlowN/A
Price / CashN/A
Book Value$1.87 per share
Price / Book13.17

Profitability

Trailing EPS($1.29)
Net Income$-28,710,000.00
Net Margins-31.24%
Return on Equity-47.37%
Return on Assets-27.29%

Miscellaneous

Employees280
Outstanding Shares25,480,000

Entellus Medical (NASDAQ:ENTL) Frequently Asked Questions

What is Entellus Medical's stock symbol?

Entellus Medical trades on the NASDAQ under the ticker symbol "ENTL."

How were Entellus Medical's earnings last quarter?

Entellus Medical Inc (NASDAQ:ENTL) released its quarterly earnings data on Thursday, November, 3rd. The medical technology company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.13. The medical technology company had revenue of $17.90 million for the quarter, compared to analysts' expectations of $17.93 million. Entellus Medical had a negative return on equity of 47.37% and a negative net margin of 31.24%. Entellus Medical's revenue for the quarter was up 20.9% on a year-over-year basis. During the same period last year, the firm posted ($0.32) earnings per share. View Entellus Medical's Earnings History.

When will Entellus Medical make its next earnings announcement?

Entellus Medical is scheduled to release their next quarterly earnings announcement on Monday, February, 19th 2018. View Earnings Estimates for Entellus Medical.

Where is Entellus Medical's stock going? Where will Entellus Medical's stock price be in 2017?

5 Wall Street analysts have issued 12-month target prices for Entellus Medical's stock. Their forecasts range from $16.00 to $25.00. On average, they expect Entellus Medical's share price to reach $19.75 in the next year. View Analyst Ratings for Entellus Medical.

What are Wall Street analysts saying about Entellus Medical stock?

Here are some recent quotes from research analysts about Entellus Medical stock:

  • 1. According to Zacks Investment Research, "Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. " (10/31/2017)
  • 2. Canaccord Genuity analysts commented, "We maintain our BUY rating following marketing meetings with management. We recently hosted Entellus Medical’s management team for a day of investor meetings in Boston. We traveled with Bob White, President and CEO and Brent Moen, CFO. Meetings were largely positive as procedural growth (both office based and OR) and reimbursement changes remain a focus for investors. We came away from those meetings with a clearer understanding of reimbursement changes, broader product portfolio, and OUS growth potential. Net, net we remain positive about Entellus’ growth opportunities despite investor uncertainty on the reimbursement front headed into 2017. Near term, as management noted on the Q3/16 conference call, we expect Entellus will set conservative guidance for 2017 to the low end of the historic 20%-25% range, and as such, set the potential for a beat and raise cadence over the H2/17. We expect reimbursement will be at the forefront of investor minds moving into 2017 as the industry digests 30-50% cuts to reimbursement in the hospital outpatient setting." (12/20/2016)

Who are some of Entellus Medical's key competitors?

Who are Entellus Medical's key executives?

Entellus Medical's management team includes the folowing people:

  • Robert S. White, President, Chief Executive Officer, Director (Age 55)
  • Brent A. Moen, Chief Financial Officer, Corporate Secretary (Age 49)
  • Michael H. Rosenthal, Chief Operating Officer (Age 43)
  • Jonelle R. Burnham, Chief Compliance Officer, Vice President, General Counsel (Age 46)
  • Stephen R. Paidosh, Vice President, Operations (Age 54)
  • Thomas D. Williamson, Vice President - Sales (Age 42)
  • Kevin L. Mensink, Vice President of Marketing (Age 44)
  • Martha J. Christian, Vice President, Reimbursement (Age 53)
  • Timothy B. Petrick, Vice President, Research and Development (Age 49)
  • Brian E. Farley, Non-Executive Chairman of the Board (Age 59)

When did Entellus Medical IPO?

(ENTL) raised $70 million in an IPO on Friday, January 30th 2015. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who owns Entellus Medical stock?

Entellus Medical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Discovery Group I LLC (8.21%), Frontier Capital Management Co. LLC (3.37%), Archon Capital Management LLC (2.16%), Aisling Capital LLC (2.08%), Wasatch Advisors Inc. (0.88%) and Cypress Capital Management LLC WY (0.26%). Company insiders that own Entellus Medical stock include Brent Moen, Brian E Farley, James D Surek, Joshua J Baltzell, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano, Robert S White, Stephen R Paidosh and Timothy B Petrick. View Institutional Ownership Trends for Entellus Medical.

Who sold Entellus Medical stock? Who is selling Entellus Medical stock?

Entellus Medical's stock was sold by a variety of institutional investors in the last quarter, including Discovery Group I LLC, Frontier Capital Management Co. LLC, Perkins Capital Management Inc., Keybank National Association OH and Wasatch Advisors Inc.. Company insiders that have sold Entellus Medical company stock in the last year include Brian E Farley, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Stephen R Paidosh and Timothy B Petrick. View Insider Buying and Selling for Entellus Medical.

Who bought Entellus Medical stock? Who is buying Entellus Medical stock?

Entellus Medical's stock was bought by a variety of institutional investors in the last quarter, including Aisling Capital LLC, Archon Capital Management LLC, Neuberger Berman Group LLC, Quantitative Systematic Strategies LLC, Citadel Advisors LLC, Eqis Capital Management Inc., JPMorgan Chase & Co. and Wells Fargo & Company MN. Company insiders that have bought Entellus Medical stock in the last two years include Brent Moen, Joshua J Baltzell and Robert S White. View Insider Buying and Selling for Entellus Medical.

How do I buy Entellus Medical stock?

Shares of Entellus Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Entellus Medical's stock price today?

One share of Entellus Medical stock can currently be purchased for approximately $24.63.

How big of a company is Entellus Medical?

Entellus Medical has a market capitalization of $619.14 million and generates $75.18 million in revenue each year. The medical technology company earns $-28,710,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Entellus Medical employs 280 workers across the globe.

How can I contact Entellus Medical?

Entellus Medical's mailing address is 3600 HOLLY LANE NORTH SUITE 40, PLYMOUTH MN, 55447. The medical technology company can be reached via phone at 763-463-1595.


MarketBeat Community Rating for Entellus Medical (ENTL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  255
MarketBeat's community ratings are surveys of what our community members think about Entellus Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Entellus Medical (NASDAQ:ENTL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.292.432.432.43
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.67$21.67$21.83$22.00
Price Target Upside: 9.68% downside15.43% upside25.91% upside69.49% upside

Entellus Medical (NASDAQ:ENTL) Consensus Price Target History

Price Target History for Entellus Medical (NASDAQ:ENTL)

Entellus Medical (NASDAQ:ENTL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017William BlairDowngradeOutperform -> Market PerformMediumView Rating Details
10/17/2017Canaccord GenuityReiterated RatingHold$17.00N/AView Rating Details
8/22/2017Piper Jaffray CompaniesReiterated RatingBuy$21.00LowView Rating Details
2/22/2017Bank of AmericaDowngradeBuy -> Underperform$16.00N/AView Rating Details
2/22/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$25.00N/AView Rating Details
11/4/2016Deutsche BankReiterated RatingBuy$25.00 -> $26.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Entellus Medical (NASDAQ:ENTL) Earnings History and Estimates Chart

Earnings by Quarter for Entellus Medical (NASDAQ:ENTL)

Entellus Medical (NASDAQ ENTL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/19/2018($0.44)N/AView Earnings Details
8/3/2017Q2 2017($0.34)($0.37)$21.87 million$22.10 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.44)($0.40)$19.61 million$19.11 millionViewListenView Earnings Details
2/21/2017Q4 2016($0.33)($0.39)$21.58 million$21.70 millionViewListenView Earnings Details
11/3/2016Q3($0.37)($0.50)$17.93 million$17.90 millionViewListenView Earnings Details
8/3/2016Q2($0.35)($0.27)$18.48 million$18.73 millionViewListenView Earnings Details
5/4/2016Q1($0.47)($0.37)$16.34 million$16.90 millionViewListenView Earnings Details
2/24/2016Q4($0.26)($0.27)$17.52 million$18.07 millionViewListenView Earnings Details
11/5/2015Q315($0.25)($0.32)$14.19 million$14.80 millionViewListenView Earnings Details
8/6/2015Q215($0.20)($0.15)$15.00 million$15.20 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Entellus Medical (NASDAQ:ENTL) Earnings Estimates

2017 EPS Consensus Estimate: ($1.54)
2018 EPS Consensus Estimate: ($1.15)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.38)($0.38)($0.38)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.37)($0.37)($0.37)
Q4 20171($0.45)($0.45)($0.45)
Q1 20181($0.34)($0.34)($0.34)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.30)($0.30)($0.30)
Q4 20181($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Entellus Medical (NASDAQ:ENTL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Entellus Medical (NASDAQ ENTL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 78.76%
Insider Trades by Quarter for Entellus Medical (NASDAQ:ENTL)
Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Entellus Medical (NASDAQ ENTL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/7/2017Brian E. FarleyDirectorSell101,319$23.85$2,416,458.15View SEC Filing  
10/20/2017Kevin L. MensinkVPSell2,500$19.00$47,500.00View SEC Filing  
10/16/2017Kevin L. MensinkVPSell10,000$18.29$182,900.00View SEC Filing  
10/9/2017Karen E PetersonVPSell650$20.17$13,110.50View SEC Filing  
10/4/2017Brian E FarleyDirectorSell40,000$19.78$791,200.00View SEC Filing  
10/4/2017Timothy B PetrickVPSell2,000$20.01$40,020.00View SEC Filing  
10/3/2017Brian E. FarleyDirectorSell6,028$19.17$115,556.76View SEC Filing  
10/2/2017Brian E. FarleyDirectorSell3,972$19.10$75,865.20View SEC Filing  
9/22/2017Timothy B. PetrickVPSell2,000$18.00$36,000.00View SEC Filing  
9/13/2017Stephen R. PaidoshVPSell25,000$17.54$438,500.00View SEC Filing  
5/8/2017Brent MoenCFOBuy6,100$12.21$74,481.00View SEC Filing  
5/8/2017Joshua J BaltzellDirectorBuy1,600$12.34$19,744.00View SEC Filing  
5/8/2017Robert S. WhiteInsiderBuy10,000$12.24$122,400.00View SEC Filing  
1/31/2017Life Sciences Fu InternationalMajor ShareholderSell533,077$17.00$9,062,309.00View SEC Filing  
1/13/2017Brian E FarleyDirectorSell14,019$20.14$282,342.66View SEC Filing  
1/13/2017Karen E. PetersonVPSell10,000$20.13$201,300.00View SEC Filing  
1/10/2017Brian E FarleyDirectorSell9,842$19.11$188,080.62View SEC Filing  
1/10/2017Karen E. PetersonVPSell9,840$19.11$188,042.40View SEC Filing  
1/4/2017Brian E FarleyDirectorSell20,158$18.74$377,760.92View SEC Filing  
1/4/2017Karen E PetersonVPSell10,160$18.74$190,398.40View SEC Filing  
12/6/2016Brian E FarleyDirectorSell15,000$18.57$278,550.00View SEC Filing  
11/23/2016Brian E FarleyDirectorSell5,000$19.00$95,000.00View SEC Filing  
11/18/2016Brian E FarleyDirectorSell10,000$18.30$183,000.00View SEC Filing  
10/13/2016Margaret A. BoianoVPSell11,103$20.01$222,171.03View SEC Filing  
10/5/2016Brian E FarleyDirectorSell30,000$22.26$667,800.00View SEC Filing  
9/8/2016James D SurekVPSell10,000$18.71$187,100.00View SEC Filing  
9/2/2016Brian E FarleyDirectorSell11,078$18.62$206,272.36View SEC Filing  
9/1/2016Brian E FarleyDirectorSell17,006$19.33$328,725.98View SEC Filing  
9/1/2016Kevin L. MensinkVPSell8,000$18.39$147,120.00View SEC Filing  
8/1/2016Kevin L MensinkVPSell8,100$17.63$142,803.00View SEC Filing  
7/18/2016Timothy B. PetrickVPSell3,000$18.15$54,450.00View SEC Filing  
2/11/2016Karen E PetersonInsiderSell5,000$16.00$80,000.00View SEC Filing  
2/4/2016Karen E PetersonInsiderSell10,000$17.00$170,000.00View SEC Filing  
9/17/2015Brian E. FarleyChairmanSell5,484$22.00$120,648.00View SEC Filing  
9/15/2015Brian E. FarleyChairmanSell27,619$22.18$612,589.42View SEC Filing  
9/14/2015Brian E. FarleyChairmanSell21,187$22.15$469,292.05View SEC Filing  
9/2/2015James D SurekVPSell15,000$21.27$319,050.00View SEC Filing  
8/31/2015James D. SurekVPSell5,000$22.29$111,450.00View SEC Filing  
2/3/2015Robert S WhiteCOOBuy5,882$17.00$99,994.00View SEC Filing  
2/3/2015Shawn MccormickDirectorBuy2,941$17.00$49,997.00View SEC Filing  
2/3/2015Woodlands Health Venture EssexMajor ShareholderBuy352,941$17.00$5,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Entellus Medical (NASDAQ ENTL) News Headlines

Source:
DateHeadline
Entellus Medical (ENTL) Rating Increased to C- at TheStreetEntellus Medical (ENTL) Rating Increased to C- at TheStreet
www.americanbankingnews.com - December 16 at 9:36 AM
 Brokerages Anticipate Entellus Medical Inc (ENTL) Will Post Earnings of -$0.45 Per Share Brokerages Anticipate Entellus Medical Inc (ENTL) Will Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - December 15 at 7:08 PM
The Law Offices of Vincent Wong Notifies Investors of an Investigation of Entellus Medical, Inc. Concerning the Sale of the Company to Stryker CorporationThe Law Offices of Vincent Wong Notifies Investors of an Investigation of Entellus Medical, Inc. Concerning the Sale of the Company to Stryker Corporation
finance.yahoo.com - December 13 at 5:02 PM
Entellus Medical (ENTL) Upgraded to Hold by ValuEngineEntellus Medical (ENTL) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - December 9 at 5:08 PM
Entellus Medical IncEntellus Medical Inc
www.bloomberg.com - December 9 at 4:48 PM
Entellus Medical (ENTL) to be Acquired by Stryker (SYK) for $24 Per Share in CashEntellus Medical (ENTL) to be Acquired by Stryker (SYK) for $24 Per Share in Cash
www.streetinsider.com - December 9 at 4:48 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Entellus Medical, Inc. to Stryker Corporation for $24.00 Per Share is Fair to ShareholdersINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Entellus Medical, Inc. to Stryker Corporation for $24.00 Per Share is Fair to Shareholders
finance.yahoo.com - December 8 at 4:48 PM
Entellus Medical (ENTL) Cut to Hold at William BlairEntellus Medical (ENTL) Cut to Hold at William Blair
www.americanbankingnews.com - December 8 at 2:34 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Entellus Medical, Inc. to Stryker Corporation for $24.00 Per Share is Fair to Shareholders – ENTLSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Entellus Medical, Inc. to Stryker Corporation for $24.00 Per Share is Fair to Shareholders – ENTL
finance.yahoo.com - December 8 at 9:59 AM
ETFs with exposure to Entellus Medical, Inc. : December 7, 2017ETFs with exposure to Entellus Medical, Inc. : December 7, 2017
finance.yahoo.com - December 8 at 9:59 AM
Is There Now An Opportunity In Entellus Medical Inc (ENTL)?Is There Now An Opportunity In Entellus Medical Inc (ENTL)?
finance.yahoo.com - December 8 at 9:59 AM
Entellus Medical, Inc. breached its 50 day moving average in a Bullish Manner : ENTL-US : December 8, 2017Entellus Medical, Inc. breached its 50 day moving average in a Bullish Manner : ENTL-US : December 8, 2017
finance.yahoo.com - December 8 at 9:59 AM
Brian E. Farley Sells 101,319 Shares of Entellus Medical Inc (ENTL) StockBrian E. Farley Sells 101,319 Shares of Entellus Medical Inc (ENTL) Stock
www.americanbankingnews.com - December 7 at 5:26 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Entellus Medical, Inc. to Stryker Corporation for $24.00 Per ...SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Entellus Medical, Inc. to Stryker Corporation for $24.00 Per ...
www.businesswire.com - December 7 at 5:13 PM
Entellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $24.00 Per Share in CashEntellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $24.00 Per Share in Cash
finance.yahoo.com - December 7 at 10:20 AM
Stryker announces definitive agreement to acquire EntellusStryker announces definitive agreement to acquire Entellus
finance.yahoo.com - December 7 at 10:20 AM
Entellus Medical to be acquired by Stryker for $24 a share in cashEntellus Medical to be acquired by Stryker for $24 a share in cash
finance.yahoo.com - December 7 at 10:20 AM
Stryker to buy Entellus Medical for $662 mlnStryker to buy Entellus Medical for $662 mln
finance.yahoo.com - December 7 at 10:20 AM
Stryker beefs up ENT business with $662 mln Entellus buyStryker beefs up ENT business with $662 mln Entellus buy
finance.yahoo.com - December 7 at 10:20 AM
$28.75 Million in Sales Expected for Entellus Medical Inc (ENTL) This Quarter$28.75 Million in Sales Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - November 29 at 6:24 AM
-$0.45 EPS Expected for Entellus Medical Inc (ENTL) This Quarter-$0.45 EPS Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - November 27 at 11:26 AM
Entellus Medical, Inc. (ENTL) Given Consensus Recommendation of "Hold" by BrokeragesEntellus Medical, Inc. (ENTL) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 23 at 10:10 AM
ETFs with exposure to Entellus Medical, Inc. : November 21, 2017ETFs with exposure to Entellus Medical, Inc. : November 21, 2017
finance.yahoo.com - November 21 at 6:31 PM
Entellus Medical to Participate in Upcoming Investor ConferencesEntellus Medical to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 14 at 6:46 PM
Anthem Inc. Issues Positive Coverage Decision for Balloon Sinus DilationAnthem Inc. Issues Positive Coverage Decision for Balloon Sinus Dilation
finance.yahoo.com - November 13 at 11:32 AM
Entellus Medical, Inc. :ENTL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017Entellus Medical, Inc. :ENTL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 13 at 11:32 AM
ETFs with exposure to Entellus Medical, Inc. : November 10, 2017ETFs with exposure to Entellus Medical, Inc. : November 10, 2017
finance.yahoo.com - November 10 at 12:53 PM
Entellus Medical, Inc. (ENTL) Expected to Post Quarterly Sales of $28.89 MillionEntellus Medical, Inc. (ENTL) Expected to Post Quarterly Sales of $28.89 Million
www.americanbankingnews.com - November 10 at 3:08 AM
 Analysts Expect Entellus Medical, Inc. (ENTL) to Post -$0.38 Earnings Per Share Analysts Expect Entellus Medical, Inc. (ENTL) to Post -$0.38 Earnings Per Share
www.americanbankingnews.com - November 8 at 9:34 PM
FY2017 EPS Estimates for Entellus Medical, Inc. (ENTL) Increased by William BlairFY2017 EPS Estimates for Entellus Medical, Inc. (ENTL) Increased by William Blair
www.americanbankingnews.com - November 6 at 6:14 AM
Is Entellus Medical Inc’s (ENTL) Balance Sheet Strong Enough To Weather A Storm?Is Entellus Medical Inc’s (ENTL) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 3 at 1:11 PM
Edited Transcript of ENTL earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of ENTL earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 5:25 AM
Entellus Medical Announces Third Quarter 2017 Financial ResultsEntellus Medical Announces Third Quarter 2017 Financial Results
www.thestreet.com - November 1 at 7:23 PM
Entellus Medical, Inc. to Host Earnings CallEntellus Medical, Inc. to Host Earnings Call
www.baystreet.ca - November 1 at 7:23 PM
Zacks Investment Research Lowers Entellus Medical, Inc. (ENTL) to HoldZacks Investment Research Lowers Entellus Medical, Inc. (ENTL) to Hold
www.americanbankingnews.com - October 31 at 11:22 PM
Entellus Announces Long-Term Data Confirming the Durable Relief of Nasal Obstruction Symptoms with Latera® from Spirox®Entellus Announces Long-Term Data Confirming the Durable Relief of Nasal Obstruction Symptoms with Latera® from Spirox®
finance.yahoo.com - October 30 at 7:03 PM
Entellus Medical, Inc. (ENTL) Receives Consensus Rating of "Hold" from BrokeragesEntellus Medical, Inc. (ENTL) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 29 at 5:38 AM
Entellus Medical, Inc. (ENTL) Scheduled to Post Earnings on WednesdayEntellus Medical, Inc. (ENTL) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 25 at 4:58 AM
Entellus Medical, Inc. (ENTL) VP Sells $47,500.00 in StockEntellus Medical, Inc. (ENTL) VP Sells $47,500.00 in Stock
www.americanbankingnews.com - October 24 at 7:38 PM
Entellus Medical, Inc. (ENTL) Expected to Announce Quarterly Sales of $22.97 MillionEntellus Medical, Inc. (ENTL) Expected to Announce Quarterly Sales of $22.97 Million
www.americanbankingnews.com - October 22 at 12:02 PM
Entellus Medical, Inc. (ENTL) VP Kevin L. Mensink Sells 10,000 SharesEntellus Medical, Inc. (ENTL) VP Kevin L. Mensink Sells 10,000 Shares
www.americanbankingnews.com - October 18 at 8:56 PM
Entellus Medical to Report Third Quarter 2017 Financial Results November 1, 2017Entellus Medical to Report Third Quarter 2017 Financial Results November 1, 2017
finance.yahoo.com - October 18 at 7:43 PM
ETFs with exposure to Entellus Medical, Inc. : October 17, 2017ETFs with exposure to Entellus Medical, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 7:06 PM
Entellus Medical, Inc. (ENTL) Earns "Hold" Rating from Canaccord GenuityEntellus Medical, Inc. (ENTL) Earns "Hold" Rating from Canaccord Genuity
www.americanbankingnews.com - October 17 at 5:16 PM
Entellus Medical, Inc. (ENTL) VP Sells $13,110.50 in StockEntellus Medical, Inc. (ENTL) VP Sells $13,110.50 in Stock
www.americanbankingnews.com - October 11 at 8:38 PM
Entellus Medical, Inc. (ENTL) Upgraded at Zacks Investment ResearchEntellus Medical, Inc. (ENTL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 9 at 7:34 PM
Entellus Medical, Inc. (ENTL) VP Timothy B. Petrick Sells 2,000 SharesEntellus Medical, Inc. (ENTL) VP Timothy B. Petrick Sells 2,000 Shares
www.americanbankingnews.com - October 6 at 8:16 PM
ETFs with exposure to Entellus Medical, Inc. : October 6, 2017ETFs with exposure to Entellus Medical, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 6:41 PM
Entellus Medical, Inc. :ENTL-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017Entellus Medical, Inc. :ENTL-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 5:29 PM
Insider Selling: Entellus Medical, Inc. (ENTL) Director Sells 3,972 Shares of StockInsider Selling: Entellus Medical, Inc. (ENTL) Director Sells 3,972 Shares of Stock
www.americanbankingnews.com - October 4 at 8:46 PM

SEC Filings

Entellus Medical (NASDAQ:ENTL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Entellus Medical (NASDAQ:ENTL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Entellus Medical (NASDAQ ENTL) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.